Abstract:Pijian Yang 1, *, Yuzhen Liang 2, *, Yunchen Luo, 2 Zhengming Li, 2 Yumei Wen, 1 Jing Shen, 1 Ruwen Li, 1 Hua Zheng, 3 Harvest F Gu 4, *, Ning Xia 1, * 1 Department of Endocrinology and Metabolism, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, People's Republic of China; 2 Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530021, People's Republic of China; 3 Life Sciences Institute, Guangxi Medical University, Nanning 530021, People's Republic of China; 4 Center for Pathophysiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009 People's Republic of China *These authors contributed equally to this work Purpose: High prevalence of nonalcoholic fatty liver disease (NAFLD) among patients with type 2 diabetes has implicated the role of hepatic insulin resistance (IR) in the diseases. To better understand the underlying mechanism, we have evaluated the pathophysiological effects of Liraglutide on NAFLD via the insulin signaling pathway. Patients and methods: A 2×2 factorial experiment was designed. High-fat diet (HFD)-induced NAFLD mice with diabetes were treated with Liraglutide for 10 weeks, while the control mice were saline-treated. Hepatic expressions of InsR, IGF-1R, IRS2, PI3K and Akt at mRNA and protein levels were analyzed with RT-PCR and Western blotting. Hematoxylin and eosin staining, Oil Red O staining and electron microscopy were used to visualize triglyceride accumulation in liver. Results: Liraglutide significantly decreased body weight, fasting blood glucose levels and HOMA-IR scores in HFD mice. Compared with the control mice fed with chow diet, hepatic expressions of InsR, IRS2, PI3K and Akt at both mRNA and protein levels in HFD mice were significantly reduced, but upregulated after Liraglutide treatment. Furthermore, Liraglutide treatment was found to improve hepatic steatosis. Conclusion: The current study thereby provides evidence that Liraglutide ameliorates NAFLD and improves hepatic steatosis mainly by upregulation of the IRS2/PI3K/Akt signaling mediators. Keywords: glucagon like peptide 1, Liraglutide, nonalcoholic fatty liver disease, insulin resistance, insulin signaling

Effects of liraglutide on fibroblast growth factor-21 and its receptors in insulin-resistant mice with hypoadiponectinemia

Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge

[The Renal Protective Effect and Mechanism of Liraglutide in Diabetic Mice Induced by High-Fat Diet].

Effect and underlying mechanism of liraglutide on fibroblast growth factor-21 production in mouse islet β cells

Effects of Liraglutide on Endoplasmic Reticulum Stress in Mice with T2DM and Fatty Livers

Glucagon-Like Peptide-1 Analogue Liraglutide Ameliorates Atherogenesis Via Inhibiting Advanced Glycation End Product-Induced Receptor for Advanced Glycosylation End Product Expression in Apolipoprotein-E Deficient Mice

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model

Effects of Liraglutide on the lipid profile in high-fat diet rats

Liver Fibroblast Growth Factor 21 (FGF21) is Required for the Full Anorectic Effect of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Male Mice fed High Carbohydrate Diets

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway

Liraglutide Alleviates Arteriosclerotic Lesions and Inhibits Receptor for Advanced Glycation End-Product Expression in Diabetic ApoE-/- Mice

Liraglutide regulates lipid metabolism via FGF21- LKB1- AMPK- ACC1 pathway in white adipose tissues and macrophage of type 2 diabetic mice

Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet

Fibroblast Growth Factor 21 Reverses Suppression of Adiponectin Expression Via Inhibiting Endoplasmic Reticulum Stress in Adipose Tissue of Obese Mice

Liraglutide Reduces Hepatic Glucolipotoxicity‑induced Liver Cell Apoptosis Through NRF2 Signaling in Zucker Diabetic Fatty Rats

Fibroblast Growth Factor-21 is Required for Weight Loss Induced by the Glucagon-like Peptide-1 Receptor Agonist Liraglutide in Male Mice fed High Carbohydrate Diets

Pharmacological Efficacy of FGF21 Analogue, Liraglutide and Insulin Glargine in Treatment of Type 2 Diabetes.

Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Protective Action of Liraglutide in Beta Cells Under Lipotoxic Stress Via PI3K/Akt/FoxO1 Pathway

Effects of Fibroblast Growth Factor-21 Gene Knockdown on the Expression of Hepatic Gluconeogenesis-Related Genes and the JAK2/STAT3 Signaling Pathway in ApoE-/-mice